Treatment of Fecal Incontinence and Functional Defecation Disorders Using Non-instrumental Biofeedback

Last updated: April 23, 2024
Sponsor: Hospital Universitari Vall d'Hebron Research Institute
Overall Status: Active - Recruiting

Phase

N/A

Condition

Fecal Incontinence

Rectal Disorders

Constipation

Treatment

Biofeedback

Placebo

Clinical Study ID

NCT06273046
PR(AG)614/2023
  • Ages 18-75
  • All Genders

Study Summary

Background. Rehabilitation and re-education using instrumental anorectal biofeedback are the main treatment of anorectal functional disorders producing incontinence and outlet obstructed defecation. These treatments imply intubation of patient and several sessions of treatment leading to high consumption of resources and costs.

Hypothesis. A cognitive intervention based on original audiovisual programs developed specifically for the management of anorectal functional disorders is effective in correcting anorectal function disorders that cause fecal incontinence and evacuation disorders.

Aim. To prove in two different protocols (fecal incontinence and dyssinergic defecation) the efficacy of specifically developed non-instrumental biofeedback techniques.

Selection criteria. Patients with fecal incontinence and altered sphincter function and patients with outlet obstructed evacuation referred for biofeedback treatment.

Intervention. In separate studies (incontinence and dyssynergic defecation) patients will be randomized into biofeedback and placebo groups. One session of either biofeedback or placebo intervention will be performed at the beginning of the intervention period and patients will be instructed to performed the assigned daily treatment at home. A visit for outcome assessment will be performed at 3 months in incontinence study and at 4 weeks in the dyssinergic defecation study. In addition, in the incontinence study a phone call will be performed after 6 months of the beginning of the study to evaluate treatment outcome.

Biofeedback: patients will be taught to control anal and abdominal muscular activity by providing instructions using original video supports. Patients will be instructed to perform the same exercises daily at home in scheduled times.

Placebo: a pill of placebo containing 0.3 g glucose will be administered every day at home.

Eligibility Criteria

Inclusion

Inclusion Criteria: Incontinence studies

  • Patients who have at least 4 episodes of fecal incontinence during the last 14 days.
  • Patients able to follow instructions and attend study visits. Dyssinergic defecation studies
  • Patients with constipation who present less than 3 complete spontaneous bowelmovements per week and/or who have Bristol 1 or Bristol 2 type stools in more than 25%of the bowel movements in the 2 weeks prior to the study
  • Patients able to follow instructions and attend study visits.

Exclusion

Exclusion Criteria:

  • Patients with organic digestive diseases such as inflammatory bowel disease, celiacdisease, gastro-duodenal ulcer...
  • Patients with neurological diseases (spinal cord injury, multiple sclerosis,Parkinson's disease).
  • Patients with previous of active colon and/or rectal cancer.
  • Patients with rectal fistula.
  • Patients with rectal prolapse.
  • Patients with total colectomy.
  • Patients who have had any radiation to the pelvis in the last month.

Study Design

Total Participants: 96
Treatment Group(s): 2
Primary Treatment: Biofeedback
Phase:
Study Start date:
April 19, 2024
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • Hospital Vall d'Hebron

    Barcelona,
    Spain

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.